Transcriptomics

Dataset Information

0

Peritoneal Metastases from Colorectal Cancer belong to Consensus Molecular Subtype 4 and are sensitized to oxaliplatin by inhibiting reducing capacity


ABSTRACT: Background: Peritoneal metastases (PM) in colorectal cancer (CRC) are associated with therapy resistance and poor survival. Oxaliplatin monotherapy is widely applied in the intraperitoneal treatment of PM, but fails to yield clinical benefit. We aimed to identify the mechanism(s) underlying PM resistance to oxaliplatin and to develop strategies overcoming such resistance. Experimental design: We generated a biobank consisting of 35 primary tumor regions and 59 paired PM from 12 patients. All samples were analyzed by RNA sequencing. We also generated a series of PM-derived organoid (PMDO) cultures and used these to design and test strategies to overcome resistance to oxaliplatin Results: PM displayed various hallmarks of aggressive CRC biology. The vast majority of PM and paired primary tumors belonged to the Consensus Molecular Subtype 4 (CMS4). PMDO cultures were resistant to oxaliplatin and expressed high levels of glutamate-cysteine ligase (GCLC) causing detoxification of oxaliplatin through glutathione synthesis. Genetic or pharmacological targeting of GCLC sensitized PMDOs to a 1-hour exposure to oxaliplatin, through increased platinum-DNA adduct formation Conclusions: These results link oxaliplatin resistance of colorectal PM to their CMS4 status and high reducing capacity. Inhibiting the reducing capacity of PM may be an effective strategy to overcome PM resistance to oxaliplatin

ORGANISM(S): Homo sapiens

PROVIDER: GSE190609 | GEO | 2022/06/15

REPOSITORIES: GEO

Similar Datasets

2024-05-01 | GSE242676 | GEO
2022-02-04 | E-MTAB-11322 | biostudies-arrayexpress
2023-08-31 | GSE119603 | GEO
2022-02-04 | E-MTAB-11321 | biostudies-arrayexpress
2022-02-05 | E-MTAB-11323 | biostudies-arrayexpress
2023-04-28 | PXD036298 | Pride
2017-08-31 | MODEL1708310001 | BioModels
2019-09-27 | PXD015369 | Pride
2023-10-24 | GSE160089 | GEO
2016-08-12 | PXD002172 | Pride